文献速递肝病

他汀类药物使用与慢性肝病患者肝硬化及相关并发症风险:系统综述与Meta分析

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-05-04

该系统综述与Meta分析纳入13项研究(3项随机试验、10项队列研究),共121058例慢性肝病患者(84.5%为丙型肝炎),46%使用他汀。他汀使用与肝硬化患者肝功能失代偿风险降低46%、死亡风险降低46%相关,与静脉曲张出血或门静脉高压进展风险降低27%相关;在无肝硬化患者中,肝硬化发生或纤维化进展风险降低58%未达统计学显著。

要点

  • 肝硬化患者使用他汀与肝功能失代偿风险降低46%相关(RR 0.54,95%CI 0.46-0.62,中等质量证据)。
  • 肝硬化患者使用他汀与死亡风险降低46%相关(RR 0.54,95%CI 0.47-0.61,中等质量证据)。
  • 3项随机对照试验中,他汀使用与静脉曲张出血或门静脉高压进展风险降低27%相关(HR 0.73,95%CI 0.59-0.91,中等质量证据)。

核心结论

  • 基于系统综述与Meta分析,他汀使用可能(probably)与慢性肝病患者肝功能失代偿和死亡风险降低相关,并可能(might)降低门静脉高压。
  • 作者认为需要前瞻性观察性研究和随机对照试验来证实这一观察结果。

研究设计与样本

  • 系统综述与Meta分析,检索截至2017年3月的文献,纳入13项研究(3项随机试验、10项队列研究),对象为成人慢性肝病患者。
  • 合并相对危险度(RR)及95%置信区间(CI)采用随机效应模型计算,并使用推荐分级的评估、制定与评价(GRADE)标准评估证据质量。

主要发现

  • 共纳入121058例慢性肝病患者(84.5%为丙型肝炎),其中46%使用他汀。
  • 肝硬化患者中,他汀使用与肝功能失代偿风险降低46%相关(4项研究;RR 0.54;95%CI 0.46-0.62;I²=0%;中等质量证据)。
  • 肝硬化患者中,他汀使用与死亡风险降低46%相关(5项研究;RR 0.54;95%CI 0.47-0.61;I²=10%;中等质量证据)。
  • 无肝硬化的慢性肝病患者中,他汀使用与肝硬化发生或纤维化进展风险降低58%相关,但未达统计学显著(5项研究;RR 0.42;95%CI 0.16-1.11;I²=99%;极低质量证据)。
  • 3项随机对照试验中,他汀使用与静脉曲张出血或门静脉高压进展风险降低27%相关(HR 0.73;95%CI 0.59-0.91;I²=0%;中等质量证据)。

关键数值与推荐

  • 肝硬化患者肝功能失代偿:RR 0.54(95%CI 0.46-0.62),I²=0%,中等质量证据。
  • 肝硬化患者死亡:RR 0.54(95%CI 0.47-0.61),I²=10%,中等质量证据。
  • 无肝硬化患者肝硬化发生或纤维化进展:RR 0.42(95%CI 0.16-1.11),I²=99%,极低质量证据,未达统计学显著。
  • 随机对照试验中静脉曲张出血或门静脉高压进展:HR 0.73(95%CI 0.59-0.91),I²=0%,中等质量证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 无肝硬化患者中肝硬化发生或纤维化进展的分析异质性 I²=99%。
  • 无肝硬化患者中肝硬化发生或纤维化进展的证据质量为极低质量。
  • 作者结论指出需要前瞻性观察性研究和随机对照试验来证实这一观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Statins have been variably shown to decrease risk and complications of chronic liver diseases (CLDs). We performed a systematic review and meta-analysis to evaluate the association between statins and risk of cirrhosis and related complications in patients with CLDs. METHODS: Through a systematic literature search up to March 2017, we identified 13 studies (3 randomized trials, 10 cohort studies) in adults with CLDs, reporting the association between statin use and risk of development of cirrhosis, decompensated cirrhosis, improvements in portal hypertension, or mortality. Pooled relative risk (RR) estimates with 95% confidence interval (CIs) were calculated using random effects model. Grading of Recommendations Assessment, Development and Evaluation criteria were used to assess quality of evidence. RESULTS: Among 121,058 patients with CLDs (84.5% with hepatitis C), 46% were exposed to statins. In patients with cirrhosis, statin use was associated with 46% lower risk of hepatic decompensation (4 studies; RR, 0.54; 95% CI, 0.46-0.62; I2 = 0%; moderate-quality evidence), and 46% lower mortality (5 studies; RR, 0.54; 95% CI, 0.47-0.61; I2 = 10%; moderate-quality evidence). In patients with CLD without cirrhosis, statin use was associated with a nonsignificant (58% lower) risk of development of cirrhosis or fibrosis progression (5 studies; RR, 0.42; 95% CI, 0.16-1.11; I2 = 99%; very-low-quality evidence). In 3 randomized controlled trials, statin use was associated with 27% lower risk of variceal bleeding or progression of portal hypertension (hazard ratio, 0.73; 95% CI, 0.59-0.91; I2 = 0%; moderate-quality evidence). CONCLUSIONS: Based on a systematic review and meta-analysis, statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs. Prospective observational studies and randomized controlled trials are needed to confirm this observation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim RG, Loomba R, Prokop LJ, et al. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017. PMID: 28479502. doi:10.1016/j.cgh.2017.04.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。